Contact this trialFirst, we need to learn more about you.
Immunomodulatory imide drugs (IMiDs)
Lenalidomide +1 More for Central Nervous System Lymphoma
Recruiting1 awardPhase 1 & 2
San Francisco, California
This trial will test a new combination therapy for relapsed central nervous system lymphoma. This is the first study to use this particular therapy, which includes an anti-CD19 antibody and an immunomodulatory drug, in patients with this type of lymphoma. The hypothesis is that the therapy will increase blood-brain barrier permeability, which could have wide-ranging implications.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.